CRVOCervoMed Inc.vs its industry peers
A metric-by-metric comparison of CervoMed Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVO본 종목 | $37M#8 | 0.0x#1 | 1.6x#11 | 9.2x#10 | -58.9%#9 | -65.6%#10 | -706.2%#9 | -117.5%#10 | -5165.9%#6 | — | — | — |
| SDEV | $42M#1 | — | 0.3x#1 | 4.3x#7 | -6.4%#5 | -8632.9%#16 | -86.3%#5 | -495.7%#12 | -7.0%#1 | — | -91.5%#11 | 11.6%#1 |
| SCYX | $41M#2 | 14.8x#4 | 0.6x#5 | 2.0x#5 | 449.9%#1 | 59.6%#2 | -78.0%#3 | -12.9%#2 | — | 7#1 | -52.1%#5 | — |
| ATNM | $40M#3 | 3.6x#3 | 1.3x#9 | 443.7x#12 | — | 11.4%#5 | -40274.4%#12 | -111.8%#8 | — | — | -22.8%#1 | — |
| VERU | $40M#4 | — | 1.4x#10 | 2.4x#6 | 3.6%#3 | 39.9%#3 | -146.6%#6 | -80.1%#6 | -399.3%#5 | — | -36.3%#2 | 0.0%#2 |
| KPTI | $39M#5 | — | — | 0.3x#1 | 0.6%#4 | -156.5%#12 | -62.1%#2 | — | — | — | -72.2%#9 | — |
| ELAB | $38M#6 | — | 2.3x#12 | 64.2x#11 | — | -24.0%#7 | -1304.4%#11 | -46.3%#5 | — | — | — | — |
| CELU | $37M#7 | — | — | 1.4x#4 | -51.0%#8 | -58.4%#9 | -230.9%#7 | — | -398.1%#4 | — | — | — |
| CNTX | $34M#9 | — | 0.9x#7 | — | — | -35.2%#8 | — | -94.6%#7 | — | — | — | — |
| LITS | $34M#10 | — | 0.6x#4 | — | -100.0%#11 | -189.7%#13 | — | -28.1%#4 | — | — | -62.4%#7 | — |
| FLNA | $33M#11 | — | 0.5x#2 | 0.8x#3 | 277.6%#2 | -273.7%#14 | -232.0%#8 | -133.5%#11 | — | — | -67.5%#8 | — |
| RMTI | $32M#12 | 267.0x#5 | 0.9x#8 | 0.5x#2 | -31.8%#7 | -1007.1%#15 | -6.8%#1 | -15.1%#3 | -14.0%#3 | 4#3 | — | — |
| BRNS | $31M#13 | — | 0.5x#3 | — | -100.0%#11 | -8.8%#6 | — | -116.4%#9 | — | — | -37.0%#3 | — |
| CPHI | $31M#14 | — | 0.9x#6 | 7.5x#9 | -8.5%#6 | 32.7%#4 | -78.2%#4 | -8.8%#1 | -7.7%#2 | 5#2 | -61.2%#6 | — |
| KYNB | $31M#15 | 0.2x#2 | — | 4.8x#8 | -78.3%#10 | 485.6%#1 | -712.7%#10 | — | — | — | -37.9%#4 | — |
| RNAZ | $31M#16 | — | — | — | — | -106.9%#11 | — | — | — | — | -83.9%#10 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice